OKUR vs. CGEN, PYXS, BHST, CTOR, ACOG, THTX, FATE, NVCT, GLSI, and IXHL
Should you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Compugen (CGEN), Pyxis Oncology (PYXS), BioHarvest Sciences (BHST), Citius Oncology (CTOR), Alpha Cognition (ACOG), Theratechnologies (THTX), Fate Therapeutics (FATE), Nuvectis Pharma (NVCT), Greenwich LifeSciences (GLSI), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry.
OnKure Therapeutics vs. Its Competitors
OnKure Therapeutics (NASDAQ:OKUR) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.
In the previous week, Compugen had 2 more articles in the media than OnKure Therapeutics. MarketBeat recorded 5 mentions for Compugen and 3 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.64 beat Compugen's score of 0.56 indicating that OnKure Therapeutics is being referred to more favorably in the media.
OnKure Therapeutics has a net margin of 0.00% compared to Compugen's net margin of -87.45%. Compugen's return on equity of -34.77% beat OnKure Therapeutics' return on equity.
OnKure Therapeutics presently has a consensus target price of $32.33, suggesting a potential upside of 988.66%. Compugen has a consensus target price of $4.00, suggesting a potential upside of 94.17%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe OnKure Therapeutics is more favorable than Compugen.
91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 2.3% of OnKure Therapeutics shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Compugen has higher revenue and earnings than OnKure Therapeutics. Compugen is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.
OnKure Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Compugen has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500.
Summary
OnKure Therapeutics and Compugen tied by winning 8 of the 16 factors compared between the two stocks.
Get OnKure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OnKure Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OKUR) was last updated on 10/16/2025 by MarketBeat.com Staff
